ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation. CMS RFC on Domestic Manufacturing. PBM Bid Transparency.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| ALEX EMERSON KEETON New | — |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| MARK RATNER | — |
Pharmacy PHA
Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Quotas on Controlled Substances. Hassan Purple Book Proposal. S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. PBM Bid Transparency. H.R.7148 - Consolidated Appropriations Act, 2026 as it relates to PBM reforms and Q1/Q2.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| ALEX EMERSON KEETON New | Senior Legislative Assistant / Deputy Communications Director / Assistant to the Chief of Staff / Legislative Correspondent / Intern - Congressman Lincoln Davis |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| MARK RATNER | — |
Copyright/Patent/Trademark CPT
H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. H.R.4570/S.1097: Interagency Patent Coordination and Improvement Act of 2025. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| MARK RATNER | — |
Trade (domestic/foreign) TRD
General Trade Issues. Drug Supply Chain. Rules of Origin. Country of Origin Labeling. Tariffs on Generic Medicines. Quotas on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. India Trade Negotiations. United States-Mexico-Canada Agreement. S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| JOHN MURPHY | — |
| MARK RATNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.